Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Dongzheng Gai, MD, Stewart JP, Xuxing Shen, Jin-Ran Chen, PhD, Can Li, MD, Bailu Peng, PhD, Ya-Wei Qiang, MD PhD, Shmuel Yaccoby, PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Guido J. Tricot, MD PhD, Lijuan Chen, MDPhD, John Shaughnessy, Jr., PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140568

Published: 2020

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2018-99-115244

Published: 2018

Journal Articles

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Brian A Walker, PhD, Cody Ashby, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2018-99-116455

Published: 2018

Journal Articles

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Whitney Tevebaugh, James Douglas, MS, Brian A Walker, PhD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J. Morgan, MD PhD, Sarah K Johnson, PhD

Blood (2017) 130 (Supplement 1): 4392.

https://doi.org/10.1182/blood.V130.Suppl_1.4392.4392

Published: 2017

Journal Articles

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Christopher P. Wardell, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2017) 130 (Supplement 1): 1790.

https://doi.org/10.1182/blood.V130.Suppl_1.1790.1790

Published: 2017

Journal Articles

Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients

Syed Mehdi, Sharmin Khan, Wen Ling, Randal S Shelton, Joshua Epstein, DSc, Ricky D Edmondson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E Davies, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2016) 128 (22): 3304.

https://doi.org/10.1182/blood.V128.22.3304.3304

Published: 2016

Journal Articles

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Blood (2016) 128 (22): 3278.

https://doi.org/10.1182/blood.V128.22.3278.3278

Published: 2016

Journal Articles

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Leo Rasche, MD, Amy Buros, PhD, Niels Weinhold, PhD, Caleb K. Stein, MS, James E McDonald, Shweta S. Chavan, PhD, Edgardo Angtuaco, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4431.

https://doi.org/10.1182/blood.V128.22.4431.4431

Published: 2016

Journal Articles

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Shmuel Yaccoby, PhD, Pingping Qu, PhD, Syed Mehdi, Antje Hoering, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 2065.

https://doi.org/10.1182/blood.V128.22.2065.2065

Published: 2016

Journal Articles

Myeloma Exosomes Prime the Microenvironment to Support Survival and Growth of Myeloma Cells

Bangzheng Chen, PhD, Sharmin Khan, Bozena M Laska, Gareth J Morgan, MD PhD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc

Blood (2016) 128 (22): 2067.

https://doi.org/10.1182/blood.V128.22.2067.2067

Published: 2016

Journal Articles

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Brian Koss, Whitney Tevebaugh, Brian A Walker, PhD, Carolina Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MD PhD, Sarah K. Johnson, PhD

Blood (2016) 128 (22): 4438.

https://doi.org/10.1182/blood.V128.22.4438.4438

Published: 2016

Journal Articles

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Caleb K. Stein, MS, Faith E Davies, MD, Christoph Heuck, MD, Niels Weinhold, PhD, Shweta S. Chavan, PhD, Brian A Walker, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Martin F Kaiser, MD, Graham H Jackson, MD PhD, Pieter Sonneveld, MD PhD, Hartmut Goldschmidt, MD, Peter Leif Bergsagel, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 4173.

https://doi.org/10.1182/blood.V126.23.4173.4173

Published: 2015

Journal Articles

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Sharmilan Thanendrarajan, MD, Daisy V. Alapat, MD, Maurizio Zangari, MD, Carolina Schinke, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Adam Rosenthal, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 1843.

https://doi.org/10.1182/blood.V126.23.1843.1843

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy

Priyangi A Malaviarachchi, BS, Donald E Turner, BS, Caleb K. Stein, MS, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2015) 126 (23): 1820.

https://doi.org/10.1182/blood.V126.23.1820.1820

Published: 2015

Journal Articles

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Blood (2015) 126 (23): 20.

https://doi.org/10.1182/blood.V126.23.20.20

Published: 2015

Journal Articles

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Blood (2015) 126 (23): 372.

https://doi.org/10.1182/blood.V126.23.372.372

Published: 2015

NARROW

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Myeloma Exosomes Prime the Microenvironment to Support Survival and Growth of Myeloma Cells

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only